US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

LEIDEN, The Netherlands, July 29, 2021 /PRNewswire/ -- VICO Therapeutics, a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products...

from PR Newswire: https://ift.tt/3f9jOyf